Skip to content
Parakho

Q1 FY27, unaudited

Revenue
₹253.79 Cr
Profit after tax
₹25.07 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations253.79+7.24%898.56
Other income5.28−4.49%24.86
Total income259.07+6.97%923.41
Employee benefit expense29.84+11.23%112.41
Finance costs3.08+19.08%12.78
Depreciation & amortisation10.80+11.57%40.15
Total expenses225.18+11.43%806.72
Profit before tax33.89−15.50%116.00
Tax expense8.82−38.78%3.09
Profit after tax25.07−2.45%112.91
Total comprehensive income25.02−2.81%112.74
Earnings per share
Earnings per share, basic₹2.33₹10.50
Earnings per share, diluted₹2.33₹10.50

Q1 FY27 unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base unaudited, from the company’s filing with NSE. Source

FY26 from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Shalby reported consolidated Q4 FY26 revenue of Rs 295.5 crore, up 9.4% year-on-year, with EBITDA rising 43.1% to Rs 37.4 crore and EBITDA margin expanding to 12.7%. Consolidated PAT for the quarter stood at Rs 18.5 crore against a loss in the same period last year, aided by a lower tax regime. Management also discussed the Shalby MedTech implant business, which posted its second consecutive quarter of positive EBITDA, and addressed the impact of the U.S.-Iran conflict on the Gurugram international hospital business.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 45 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 20 Aug 2026.